32 results about "Antigen uptake" patented technology

An objective of the present invention is to provide methods for facilitating antigen-binding molecule-mediated antigen uptake into cells, methods for facilitating the reduction of antigen concentration in plasma, methods for increasing the number of antigens to which a single antigen-binding molecule can bind, methods for improving pharmacokinetics of antigen-binding molecules, antigen-binding molecules improved for facilitated antigen uptake into cells, antigen-binding molecules capable of facilitating the reduction of antigen concentration in plasma, antigen-binding molecules capable of repeatedly binding to antigens, antigen-binding molecules with improved pharmacokinetics, pharmaceutical compositions comprising such an antigen-binding molecule, and methods for producing those described above.The present inventors discovered that antigen uptake into cells is facilitated by an antibody having human FcRn-binding activity at the plasma pH and a lower antigen-binding activity at the early endosomal pH than at the plasma pH; such antibodies can increase the number of antigens to which a single antibody molecule can bind; the reduction of antigen in plasma can be facilitated by administering such an antibody; and antibody pharmacokinetics can be improved by using such antibodies.

The present invention provides: a modified FcRn-binding domain having an enhanced affinity for the Fc Receptor neonatal (FcRn) at neutral pH; an antigen-binding molecule comprising said FcRn-binding domain, which has low immunogenicity, high stability and form only a few aggregates; a modified antigen-binding molecule having an increased FcRn-binding activity at neutral or acidic pH without an increased binding activity at neutral pH for a pre-existing anti-drug antibody; use of the antigen-binding molecules for improving antigen-binding molecule-mediated antigen uptake into cells; use of the antigen-binding molecules for reducing the plasma concentration of a specific antigen; use of the modified FcRn-binding domain for increasing the total number of antigens to which a single antigen-binding molecule can bind before its degradation; use of the modified FcRn-binding domain for improving pharmacokinetics of an antigen-binding molecule; methods for decreasing the binding activity for a pre-existing anti-drug antibody; and methods for producing said antigen-binding molecules.

An objective of the present invention is to provide methods for facilitating antigen-binding molecule-mediated antigen uptake into cells, methods for facilitating the reduction of antigen concentration in plasma, methods for increasing the number of antigens to which a single antigen-binding molecule can bind, methods for improving pharmacokinetics of antigen-binding molecules, antigen-binding molecules improved for facilitated antigen uptake into cells, antigen-binding molecules capable of facilitating the reduction of antigen concentration in plasma, antigen-binding molecules capable of repeatedly binding to antigens, antigen-binding molecules with improved pharmacokinetics, pharmaceutical compositions comprising such an antigen-binding molecule, and methods for producing those described above.The present inventors discovered that antigen uptake into cells is facilitated by an antibody having human FcRn-binding activity at the plasma pH and a lower antigen-binding activity at the early endosomal pH than at the plasma pH; such antibodies can increase the number of antigens to which a single antibody molecule can bind; the reduction of antigen in plasma can be facilitated by administering such an antibody; and antibody pharmacokinetics can be improved by using such antibodies.

Dendritc cells play a critical role in antigen-specific immune responses. Materials and methods are provided for treating disease states, including cancer and autoimmune disease, by facilitating or inhibiting the migration or activation of antigen-presenting dendritic cells. In particular, chemokines are used to initiate, amplify or modulate an immune response. In one embodiment, chemokines are used to attract dentritic cells to the site of antigen delivery. An increase number of dendritic at the site of antigen delivery means more antigen uptake and a modified immune response.

Transcutaneous immunization can deliver antigen to the immune system through the stratum corneum without physical or chemical penetration to the dermis layer of the skin. This delivery system induces an antigen-specific immune response. Use of skin-active adjuvants is preferred. Although perforation of intact skin is not required, superficial penetration or micropenetration of the skin can act as an enhancer; similarly, hydration may enhance the immune response. This system can induce antigen-specific immune effectors after epicutaneous application of a formulation containing one or more antigen and adjuvant. The formulation may initiate processes such as antigen uptake, processing, and presentation; Langerhans cell activation, migration from the skin to other immune organs, and differentiation to mature dendritic cells; contacting antigen with lymphocytes bearing cognate antigen receptors on the cell surface and their stimulation; and combinations thereof. Systemic and / or regional immunity may be induced; immune responses that result in prophylaxis and / or therapeutic treatments are preferred. Antigen and adjuvant activities in the formulation may be found in the same molecule, two or more different molecules dissociated from each other, or multiple molecules in a complex formed by covalent or non-covalent bonds. For antigens and adjuvants which are proteinaceous, they may be provided in the formulation as a polynucleotide for transcutaneous genetic immunization. Besides simple application of a liquid formulation, patches or other medical devices may be used to deliver antigen for immunization.

The invention covers the use of certain classes of lipids including cationic lipids in ex-vivo dendritic cell therapies. The cationic lipids enhance antigen uptake, processing and presentation of the processed antigens by dendritic cells to CD8+and CD4+T-cells via the MHC classes I and II presentation pathways respectively. Antigen uptake via cationic lipid by dendritic cells result in significant lowering of the population of the immune suppressive regulatory T cells in the tumors and a significant increase of the tumor targeting cytotoxic T-cells. Loss of regulatory T cells and increase of tumor specific cytotoxic cells are conducive to effective elimination of the tumors.

Provided is a pharmaceutical composition for preventing or treating cancer, and more particularly, a pharmaceutical composition for preventing or treating cancer, including dendritic cells with a knock-down Dab2 gene. The composition includes a dendritic cell in which a Dab2 gene is knocked down or knocked out or activity of a Dab2 protein is suppressed as an active ingredient, and thus is expected to be useful as a pharmaceutical composition to prevent, improve or treat cancer as a result of having improved antigen uptake, a migration ability of a cell to a lymph node, and expression of inflammatory cytokines, and activating antigen-specific cytotoxic T cell lymphocyte (CTL) and related T cells that can attack cancer cells, and therefore is expected to be used as the pharmaceutical composition for preventing, improving or treating cancer.

The invention discloses an application of embelin to the preparation of a medicament for treating an autoimmune disease. As proved by an experimental result, the embelin can be used for suppressing the differentiation of human immune dendritic cells, the maturity of human immune dendritic cells activated by LPS (Lipopolysaccharide), the antigen uptaking capabilities of immature dendritic cells, the antigen presenting capabilities of mature dendritic cells, cell-T breeder reactions excited by dendritic cells, and the expression of cell factors which are secreted by dendritic cells and are usedfor promoting type 1 and type 17 cell differentiation of auxiliary cells T. Particularly, the embelin can be used for lowering the pathogenic degree of mouse experimental autoimmune encephalomyelitis. The invention relates to preparation of a medicament for suppressing an immune system, which can become a medicament for clinically treating autoimmune inflammatory lesions such as multiple sclerosis, acute disseminated encephalomyelitis and the like.

The invention provides an adjuvant for a desensitization vaccine, which includes an immune tolerance-inducing component, and the immune tolerance-inducing component is an anti-inflammatory compound. The present invention also provides a novel desensitizing vaccine using an anti-inflammatory compound as an adjuvant. In the present invention, the anti-inflammatory compound is used as an adjuvant and co-injected with the allergen to prevent the inflammation of the allergic vaccine at the site; the anti-inflammatory compound has the effect of inhibiting the maturation of antigen-presenting cells, and the anti-inflammatory compound directly acts on the antigen-presenting cells, inhibiting They become mature cells during antigen uptake and presentation; anti-inflammatory compounds achieve long-lasting treatment of allergies by rapidly inducing the generation of Treg cells. The desensitization vaccine provided by the invention can realize rapid, long-acting and effective treatment of allergic symptoms from the mechanism of sensitization.

This application belongs to the technical field related to protein for tumor therapy, and specifically relates to an affinity peptide TY peptide targeting dendritic cells and its application patent application matters. The TY peptide is a 12-peptide, and the specific amino acid sequence is: TITHFQFGPTVY. On the basis of TY peptide, this application further designed a new type of nano-transport system that can target DC based on MSN, and loaded the model antigen OVA and immune adjuvant CpG, and successfully prepared the nano-carrier MSN‑TY / OVA / CpG. Experiments show that MSN‑TY / OVA / CpG can be effectively taken up by immature DCs, improve the efficiency of antigen uptake by DCs, promote the maturation of DCs and effectively activate DCs, and effectively promote the processing and presentation of antigens , stimulate its secretion of cytokines, and further trigger antigen-specific CTL immune response and anti-tumor immune response.